High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli

Arne Søraas, Arnfinn Sundsfjord, Silje Bakken Jørgensen, Knut Liestøl, Pål A Jenum, Arne Søraas, Arnfinn Sundsfjord, Silje Bakken Jørgensen, Knut Liestøl, Pål A Jenum

Abstract

A population-based study was performed to investigate the efficacy of mecillinam treatment of community-acquired urinary tract infections (CA-UTI) caused by extended-spectrum β-lactamase (ESBL) producing Escherichia coli. The study was conducted in South-Eastern Norway. Data from patients with CA-UTI caused by ESBL-producing and non-producing (random controls) E. coli were collected through interviews, questionnaires, medical records and the Norwegian Prescription Database. Treatment failure was defined as a new antibiotic prescription appropriate for UTI prescribed within two weeks after the initial antimicrobial therapy. Multivariable logistic regression analysis was performed to identify treatment agents and patient- or bacterial traits associated with treatment failure. A total of 343 patients (mean age 59) were included, of which 158 (46%) were treated with mecillinam. Eighty-one patients (24%, mean age 54) had infections caused by ESBL producing E. coli, and 41 of these patients (51%) received mecillinam as the primary treatment. Mecillinam treatment failure was observed in 18 (44%) of patients infected by ESBL-producing strains and in 16 (14%) of patients with a CA-UTI caused by ESBL non-producing strains. Multivariable analysis showed that ESBL status (odds ratio (OR) 3.2, 95% confidence interval (CI) 1.3-7.8, p = 0.009) and increased MIC of mecillinam (OR 2.0 for each doubling value of MIC, CI 1.4-3.0, p<0.001) were independently associated with mecillinam treatment failure. This study showed a high rate of mecillinam treatment failure in CA-UTIs caused by ESBL producing E. coli. The high failure rate could not be explained by the increased MIC of mecillinam alone. Further studies addressing the use of mecillinam against ESBL-producing E. coli, with emphasis on optimal dosing and combination therapy with β-lactamase inhibitors, are warranted.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Mecillinam treatment failure rate among…
Figure 1. Mecillinam treatment failure rate among patients with community-acquired urinary tract infection caused by ESBL-producing and non-ESBL-producing E. coli with different mecillinam mean inhibitory concentrations.

References

    1. Garau J (2008) Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 14 Suppl 1198–202.
    1. Sougakoff W, Jarlier V (2000) Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases. J Antimicrob Chemother 46 Suppl 19–14.
    1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, et al. (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52: e103–e120.
    1. Dewar S, Reed LC, Koerner RJ (2013) Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother.
    1. Sullivan A, Edlund C, Svenungsson B, Emtestam L, Nord CE (2001) Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora. J Chemother 13: 299–308.
    1. Sullivan A, Fianu-Jonasson A, Landgren BM, Nord CE (2005) Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. Antimicrob Agents Chemother 49: 170–175.
    1. Kahlmeter G, Poulsen HO (2012) Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 39: 45–51.
    1. NORM/NORM-VET 2010 (2011) Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo 2011. ISSN:1502–2307 (print)/1890–9965 (electronic).
    1. Tarnberg M, Ostholm-Balkhed A, Monstein HJ, Hallgren A, Hanberger H, et al. (2011) In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 30: 981–987.
    1. Titelman E, Iversen A, Kalin M, Giske CG (2012) Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 18: 189–192.
    1. Auer S, Wojna A, Hell M (2010) Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 54: 4006–4008.
    1. Wootton M, Walsh TR, Macfarlane L, Howe RA (2010) Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 65: 79–81.
    1. Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, et al. (2012) Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 67: 2424–2428.
    1. Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D (2006) Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 57: 367–368.
    1. Nicolle LE, Mulvey MR (2007) Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 39: 748–749.
    1. Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA (2013) Risk Factors for Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Enterobacteriaceae -A Case-Control Study in a Low Prevalence Country. PLoS One 8: e69581.
    1. Berg C, Furu K, Mahic M, Litleskare I, Rønning M et al... (2011) The Norwegian Prescription Database 2006–2010: The Norwegian Institute of Public Health. ISBN: 978-82-8082-458-5.
    1. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Available: 1 October 2013.
    1. Birkett CI, Ludlam HA, Woodford N, Brown DF, Brown NM, et al. (2007) Real-time TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum beta-lactamases. J Med Microbiol 56: 52–55.
    1. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, et al. (2007) Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 45: 199–205.
    1. Lawrenson RA, Logie JW (2001) Antibiotic failure in the treatment of urinary tract infections in young women. J Antimicrob Chemother 48: 895–901.
    1. Goettsch WG, Janknegt R, Herings RM (2004) Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol 58: 184–189.
    1. Bjerrum L, Dessau RB, Hallas J (2002) Treatment failures after antibiotic therapy of uncomplicated urinary tract infections. A prescription database study. Scand J Prim Health Care 20: 97–101.
    1. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37: 360–363.
    1. Livermore DM (2012) Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 27: 128–142.
    1. Naseer U, Sundsfjord A (2011) The CTX-M conundrum: dissemination of plasmids and Escherichia coli clones. Microb Drug Resist 17: 83–97.
    1. Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17: 479–501.
    1. Kerrn MB, Frimodt-Moller N, Espersen F (2004) Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole. Clin Microbiol Infect 10: 54–61.
    1. Jensen KS, Henriksen AS, Frimodt-Moeller N (2008) Pivmecillinam: estimation of adequate dosage for susceptible and ESBL-producing E. coli by Monte Carlo PK/PD simulation. Abstracts of the 18nd European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2008 Abstract P1255 European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
    1. Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rasmussen SN, et al. (2000) Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother 44: 156–163.
    1. Frimodt-Moller N (2002) Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19: 546–553.
    1. Bjerrum L, Gahrn-Hansen B, Grinsted P (2009) Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial. Scand J Prim Health Care 27: 6–11.
    1. Menday AP (2000) Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection. Int J Antimicrob Agents 13: 183–187.
    1. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ (2007) Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 25: 49–57.
    1. Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N, et al. (2002) Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 34: 487–492.
    1. Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, et al. (2000) Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 30: 152–156.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe